Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.
Salivary Gland Cancer
DRUG: Nivolumab|DRUG: Ipilimumab
best overall response rate, using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1), 2 years
The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.